Form 4: Milestone Pharmaceuticals Director Robert James Wills Granted 40,000 Stock Options

Milestone Pharmaceuticals Inc. Director Robert James Wills was granted 40,000 stock options with an exercise price of $1.75, vesting over 12 months starting July 10, 2025.

Summary

• Robert James Wills, a Director of Milestone Pharmaceuticals Inc. (MIST), was granted 40,000 stock options.
• The stock options have an exercise price of $1.75 per share.
• The grant date for these options was June 10, 2025.
• The options will vest in twelve equal monthly installments, commencing on July 10, 2025.
• The options will be fully vested on the date of the next annual meeting of the stockholders of the Issuer, provided Mr. Wills continues to provide service through each vesting date.
• The expiration date for these stock options is June 10, 2035.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event that aligns the director's interests with the company's long-term performance, indicating continued commitment. It is a neutral to slightly positive event as it's standard practice.

Positives

• Grant of 40,000 stock options to Director Robert James Wills, which aligns his interests with long-term shareholder value.
• The options have a 10-year expiration date (June 10, 2035), providing a substantial window for potential exercise and value realization.

Future Outlook

NA

Industry Context

This Form 4 filing is a standard disclosure of an insider transaction, specifically the grant of equity compensation to a director. It does not provide information on broader industry trends or competitive landscape, but rather details a specific compensation event within Milestone Pharmaceuticals Inc.

Related Party Transactions

• Grant of 40,000 stock options to Robert James Wills, a Director of Milestone Pharmaceuticals Inc., as part of his compensation package.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with share price appreciation, potentially benefiting shareholders if the company performs well. However, future exercise of these options could lead to minor dilution.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Robert James Wills must continue to provide service to Milestone Pharmaceuticals Inc. for the stock options to vest according to the schedule.
• The stock options will fully vest by the date of the next annual meeting of the stockholders of the Issuer.
• Robert James Wills may choose to exercise the vested options at the exercise price of $1.75 per share before the expiration date of June 10, 2035.

Key Dates

Keywords

Milestone Pharmaceuticals, MIST, SEC Form 4, Stock Options, Director Compensation, Insider Transaction, Robert James Wills